Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept

Annals of the Rheumatic Diseases

Volumn 64, Issue 2, 2005, Pages 246-252

  Feltelius, Nils ^a   Fored, C M ^b   Blomqvist, P ^b   Bertilsson, L ^c   Geborek, P ^d   Jacobsson, L T ^d   Lindblad, S ^b   Lysholm, J ^e   Rantapaa Dahlqvist S ^f   Saxne, T ^d   Klareskog, L ^b  

^a MEDICAL PRODUCTS AGENCY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e FALUN HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; AURANOFIN; AUROTHIOMALATE; AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CPH 82; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ABSCESS; ADULT; ANGINA PECTORIS; ARTICLE; ASYSTOLE; BILIARY TRACT DISEASE; BLOOD DISEASE; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COLLAGEN DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSARTHRIA; ENCEPHALITIS; ENDOCRINE DISEASE; FACIAL NERVE PARALYSIS; FEVER; FOLLOW UP; GASTROENTERITIS; GASTROINTESTINAL TUMOR; HEADACHE; HEARING IMPAIRMENT; HEART FAILURE; HEART INFARCTION; HUMAN; INFECTION; INFECTIOUS ARTHRITIS; LEUKOPENIA; LIVER CANCER; LIVER DISEASE; LIVER TUMOR; LUNG EDEMA; LYMPHOMA; MAJOR CLINICAL STUDY; MENTAL DISEASE; METABOLIC DISORDER; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; OSTEITIS; OVARY CANCER; PANCYTOPENIA; PARESTHESIA; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RECTUM CANCER; REPRODUCTIVE TOXICITY; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT TUMOR; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEPSIS; SIDE EFFECT; SKIN INFLAMMATION; SKIN MANIFESTATION; SOFT TISSUE DISEASE; SUBARACHNOID HEMORRHAGE; SWEDEN; TACHYCARDIA; THROMBOCYTOPENIA; TOOTH DISEASE; TREATMENT OUTCOME; URINARY TRACT DISEASE; UTERINE CERVIX CANCER; VASCULAR DISEASE; VEIN THROMBOSIS; VESTIBULAR DISORDER; VISUAL IMPAIRMENT;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PHARMACOEPIDEMIOLOGY; PRODUCT SURVEILLANCE, POSTMARKETING; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SWEDEN; TREATMENT OUTCOME;

EID: 19944433874     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.023473     Document Type: Article

References (18)

1. US Department of Health and Human Services. Food and Drug Administration. Fast track drug development programs-designation, development, and application review, 1998. (Website accessed 9 March 2004, at: http://www.fda.gov/cder/ guidance/2112fnl.pdf).
2. Wolfe F, Fries JF. Rate of death due to leukemia/lymphoma in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:2694-5.
3. National Institute for Clinical Excellence (NICE). Faster access to modern treatment-objectives, 2003. (Website accessed 9 March 2004, at: http://www.nice.org.uk/article.asp?a=289).
4. European Agency for the Evaluation of Medicinal Products (EMEA). ICH E2E - Pharmacovigilance Planning (PVP). CPMP/ICH/5716/03. 2003. (Website accessed 9 March 2004, at: http://www.emea.eu.int/pdfs/human/ich/571603en.pdf).
5. Moride Y, Haramburu F, Requejo AA, Begaud B. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol 1997;43:177-81.
6. Bates DW, Evans RS, Murff H, Stetson PD, Pizziferri L, Hripcsak G. Detecting adverse events using information technology. J Am Med Inform Assoc 2003;10:115-28.
7. European Agency for the Evaluation of Medicinal Products (EMEA). Work programme for the European Agency for the Evaluation of Medicinal Products 2004. EMEA/MB/58/03/en/Final. 2003. (Website accessed 9 March 2004, at: http://www.emea.eu.int/pdfs/general/direct/emeawp/005803en.pdf).
8. van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
9. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
10. European Agency for the Evaluation of Medicinal Products (EMEA). ICH Topic E2A-Clinical safety data management: definitions and standards for expedited reporting. CPMP/ICH/377/95. 1995. (Website accessed 4 May 2004, at: http://www.emea.eu.int/pdfs/human/ich/037795en.pdf).
11. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceutical for Human Use (ICH). ICH-endorsed guide for MedDRA users, MedDRA term selection: points to consider, 2002. (Website accessed 9 March 2004, at: http://www.ich.org/MediaServer.jser?@_ID=595&@_MODE=GLB).
12. Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2003:CD004525.
13. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
14. Morrison A. Screening. In: Rothman K, Greenland S, eds. Modern epidemiology, 2nd ed. Philadelphia: Lippincott-Raven, 1998:499-518.
15. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999;281:824-9.
16. Swedish Medical Products Agency. The Swedish Medical Products Agency Annual Report 2003 (In Swedish). 2004. (Website accessed 9 March 2004, at: http://www.mpa.se/om_verket/publikationer/LV-ARR-2003.pdf).
17. National Board of Health and Welfare. Yearbook of health and medical care 2001, Bases for the Swedish health care [in Swedish], 2001. (Website accessed 9 March 2004, at: http://www.sos.se/FULLTEXT/111/2001-111-6/Kap3.pdf).
18. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.